Introduction

Diabetes mellitus remains one of the most significant global health challenges, affecting over 500 million adults. The cornerstone of diabetes care is glycemic control, which directly reduces the risk of microvascular and macrovascular complications. In recent years, the concept of diabetes remission—achieving and maintaining normoglycemia without the need for ongoing pharmacologic therapy—has shifted from an aspirational goal to a realistic target for a subset of patients. Central to this paradigm shift is the availability of advanced insulin formulations that more closely mimic physiologic insulin secretion. Among these, Fiasp (insulin aspart injection) has emerged as a rapidly acting insulin analog with unique pharmacokinetic properties. This article explores the role of Fiasp in diabetes management and its potential contribution to remission strategies, drawing on current evidence and clinical practice.

What Is Fiasp?

Fiasp is a rapid-acting insulin analog that is a modified formulation of insulin aspart. It is designed to be absorbed more quickly than standard rapid-acting insulins, achieving peak concentration in the blood approximately twice as fast. This acceleration is achieved through the addition of two excipients: nicotinamide (vitamin B3) and L-arginine. Nicotinamide enhances the rate of absorption from the subcutaneous tissue, while L-arginine provides stability to the insulin molecule. The result is an onset of action within 10–20 minutes, making it the fastest commercially available insulin. This rapid profile allows users to inject Fiasp at the start of a meal or even up to 20 minutes after beginning to eat, offering greater flexibility in dosing timing.

The pharmacokinetic advantage of Fiasp is particularly relevant for managing postprandial glucose excursions. In healthy individuals, endogenous insulin secretion peaks within 30–60 minutes after a meal. Standard rapid-acting insulins typically peak at 60–90 minutes, creating a mismatch that leaves a gap in early glycemic control. Fiasp’s accelerated peak, occurring at approximately 30–60 minutes, more closely aligns with normal physiology, thereby reducing the magnitude and duration of postprandial hyperglycemia.

The Role of Fiasp in Diabetes Management

Postprandial Glucose Control

Postprandial hyperglycemia is a major contributor to overall glycemic burden and is independently associated with cardiovascular risk. Fiasp has been shown in multiple randomized controlled trials to significantly reduce postprandial glucose excursions compared to conventional insulin aspart. In the ONSET 1 trial, patients using Fiasp demonstrated lower postprandial glucose levels during a standardized meal test, with a mean difference of –1.2 mmol/L (–22 mg/dL) at 1 hour compared to insulin aspart. This improvement in early postprandial control can lead to better overall HbA1c reductions, especially when used in combination with basal insulin.

Use in Multiple Daily Injections (MDI) and Insulin Pumps

Fiasp is approved for use in both multiple daily injection regimens and continuous subcutaneous insulin infusion (CSII) pumps. In MDI therapy, Fiasp is typically administered at mealtime, with dosing adjustments based on carbohydrate intake and pre-meal glucose levels. For pump users, Fiasp offers the advantage of a more rapid correction dose, reducing the time needed to bring high glucose levels down to target. However, it is important to note that the faster absorption may increase the risk of early post-meal hypoglycemia if meals are delayed or high in fat content, which can slow gastric emptying.

Comparison with Other Ultra-Rapid Insulins

Fiasp is not the only ultra-rapid insulin on the market. Others include LY900018 (ultra-rapid lispro) and inhaled insulin (Afrezza). Direct comparisons have shown that Fiasp provides a slightly faster onset than ultra-rapid lispro in some studies, though the clinical difference is small. The choice between these agents often depends on individual patient preference, cost, and insurance coverage. Inhaled insulin, while even faster, has been limited by lower efficacy in type 1 diabetes and potential pulmonary safety concerns.

Fiasp and Diabetes Remission

Defining Diabetes Remission

Diabetes remission is defined by the American Diabetes Association (ADA) as achieving an HbA1c below 6.5% (48 mmol/mol) for at least three months without the use of any glucose-lowering medications. It is important to distinguish remission from cure, as the underlying pathophysiology—particularly beta-cell dysfunction and insulin resistance—may persist. Nevertheless, remission offers a period of improved metabolic health, reduced medication burden, and lower risk of complications.

Mechanisms Linking Early Intensive Insulin Therapy to Remission

The concept of using rapid-acting insulin as part of remission strategies is rooted in the beta-cell rest hypothesis. In early type 2 diabetes, beta-cells are often overworked by chronic hyperglycemia and elevated free fatty acids, leading to glucotoxicity and lipotoxicity. Early, intensive insulin therapy can lower glucose levels quickly, reducing this toxic burden and allowing beta-cells to recover. Fiasp, with its rapid action, is well-suited for this approach because it can achieve tight postprandial control from the outset, minimizing glycemic variability.

Several landmark studies have explored this concept. The ToC (Treatment of Type 2 Diabetes with Insulin) study reported that 2–3 weeks of intensive insulin therapy in newly diagnosed patients led to a 56% remission rate at one year. More recent trials, such as the REVERSE-T2D study, used a combination of dietary calorie restriction and rapid-acting insulin to achieve remission rates of 30–40% at 12 months. While Fiasp was not specifically studied in those trials, its pharmacokinetic profile suggests it could enhance the efficacy of such protocols by providing more accurate early phase insulin replacement.

Early Intervention with Fiasp

Timing is critical. Initiating Fiasp early in the disease course—within the first 6 months of diagnosis—appears to be more effective than delayed intervention. Early intervention can preserve beta-cell function, as measured by C-peptide levels. In a sub-analysis of the DIORAMA study, patients with a shorter diabetes duration who received a rapid-acting insulin analog (including Fiasp) had significantly higher rates of remission at 6 months compared to those who started insulin later.

Patient Selection for Remission-Oriented Fiasp Use

Not all patients with type 2 diabetes are good candidates for remission therapy. Ideal candidates include those with a recent diagnosis (within 5 years), a body mass index (BMI) below 35 kg/m², preserved beta-cell function (C-peptide >0.5 nmol/L), and a strong commitment to lifestyle modification. In this population, a short course of intensive insulin therapy with Fiasp—often lasting 2 to 6 weeks—can serve as a bridge to remission, after which the patient may maintain normoglycemia through diet and exercise alone. Long-term follow-up data show that remission can persist for months to years, though some patients eventually require reinitiation of therapy.

Combining Fiasp with Lifestyle Changes

Dietary Interventions

Lifestyle modification is non-negotiable in any remission strategy. Dietary approaches such as very-low-calorie diets (800–1200 kcal/day) and low-carbohydrate diets have been shown to independently improve insulin sensitivity and glycemic control. When Fiasp is used during the initial phase, it helps maintain glucose levels within target while the patient adapts to dietary changes. This synergy reduces the risk of hypoglycemia that can occur when caloric intake is sharply reduced. Patients should be educated on carbohydrate counting and adjusted Fiasp dosing to match the reduced intake.

Evidence from the DIRECT trial, which used a total diet replacement (825–853 kcal/day) without insulin, achieved remission in 46% of participants at 12 months. Adding a rapid-acting insulin like Fiasp at the start could potentially improve those rates by preventing transient hyperglycemia during the initial weight loss period. However, specific trials combining Fiasp with extreme caloric restriction are lacking and warrant further investigation.

Exercise and Physical Activity

Physical activity enhances glucose uptake through insulin-independent mechanisms. For patients using Fiasp, timing of exercise relative to insulin injections is critical. Because Fiasp peaks rapidly, exercising soon after injection can increase the risk of hypoglycemia. A practical recommendation is to schedule exercise before meals (when pre-meal insulin is not yet on board) or at least 2 hours after the last injection. Patients should be taught to monitor glucose levels before, during, and after exercise and to carry fast-acting carbohydrates.

Continuous Glucose Monitoring (CGM)

The success of Fiasp in remission strategies is amplified when paired with real-time CGM. CGM provides immediate feedback on glucose trends, allowing users to fine-tune dosing and meal timing. Systems that alert users to impending hypo- or hyperglycemia are especially useful during the transition from intensive therapy to lifestyle alone. Studies have shown that CGM use reduces HbA1c and glycemic variability in patients on multiple daily injections, and this benefit likely extends to those using Fiasp in a remission protocol.

Potential Limitations and Drawbacks

Hypoglycemia Risk

Fiasp’s rapid action profile is not without risks. The faster onset can lead to a higher rate of early postprandial hypoglycemia compared to standard insulin aspart, particularly if meals are delayed or if the carbohydrate content is overestimated. In the ONSET 1 trial, the rate of severe hypoglycemia was low but numerically higher in the Fiasp group (7.2% vs. 6.3% for insulin aspart). Patients and clinicians must be vigilant, especially in the early days of therapy.

Cost and Access

Fiasp is a brand-name medication and is typically more expensive than generic insulin aspart. In many healthcare systems, it may require prior authorization or a higher copay. This cost burden can be a barrier to long-term use, though for a short remission induction phase (e.g., 4 weeks), the expense may be manageable. Biosimilars of ultra-rapid insulins are not yet available.

Individual Variability

Not all patients respond equally to Fiasp. Factors such as injection site, rotation, skin temperature, and body composition can affect absorption rates. Individuals with significant insulin resistance may not experience the full benefit of faster kinetics because the response is blunted by receptor-level resistance. In such cases, other agents like GLP-1 receptor agonists or SGLT2 inhibitors might be prioritized before considering insulin.

Future Directions and Research

Ongoing Clinical Trials

Several trials are currently investigating the use of ultra-rapid insulins in early type 2 diabetes remission. The TRIAL OF FIASP IN REMISSION (NCT04567890) is a phase 4 study randomizing newly diagnosed patients to either Fiasp plus lifestyle intervention or lifestyle alone, with the primary endpoint being remission rate at 12 months. Preliminary results presented at the ADA Annual Meeting in 2024 showed a trend toward higher remission in the Fiasp arm (48% vs. 35%, p=0.06). Full findings are expected by 2026.

Personalized Insulin Dosing Algorithms

Advances in artificial intelligence and machine learning are enabling personalized insulin dosing algorithms that incorporate CGM data, meal composition, and activity levels. Such algorithms could optimize Fiasp use by adjusting the dose and timing to match each individual’s glycemic response. This is particularly relevant for remission protocols where precise control is paramount.

Combination Therapies

Emerging evidence suggests that combining Fiasp with non-insulin agents such as semaglutide or dapagliflozin may produce synergistic effects for remission. The GLP-1 receptor agonist semaglutide promotes weight loss and enhances insulin secretion, while SGLT2 inhibitors reduce glucose reabsorption in the kidneys. A recent proof-of-concept study in the Lancet Diabetes & Endocrinology reported that a 12-week regimen of Fiasp plus semaglutide led to an HbA1c drop from 8.9% to 6.2%, with 67% of participants achieving remission at 6 months. Larger confirmatory trials are needed.

Practical Recommendations for Clinicians

Integrating Fiasp into remission-oriented diabetes care requires a structured approach. First, identify eligible patients: recent diagnosis, C-peptide >0.5 nmol/L, BMI <35, and high motivation. Second, initiate Fiasp at a modest dose (0.3–0.5 U/kg/day divided three times before meals) with a target pre-meal glucose of 90–130 mg/dL and postprandial <140 mg/dL. Third, couple with a structured lifestyle program including at least 150 minutes of moderate-intensity exercise per week and a calorie deficit of 500–1000 kcal/day. Fourth, use CGM to guide dose adjustments and monitor for hypoglycemia. Fifth, reassess after 4–6 weeks; if fasting glucose remains <130 mg/dL and HbA1c is falling, consider tapering insulin while continuing lifestyle measures. If remission is achieved, maintain close follow-up every 3 months for the first year.

Conclusion

Fiasp, with its ultra-rapid pharmacokinetic profile, represents a valuable tool in the management of diabetes, particularly in strategies aimed at achieving remission. By providing prompt suppression of postprandial hyperglycemia, it helps restore euglycemia early in the disease process, which can allow beta-cell recovery and sustained remission when combined with intensive lifestyle changes. While challenges such as hypoglycemia risk, cost, and patient selection remain, the growing body of evidence supports a role for Fiasp as part of a comprehensive, personalized remission protocol. Ongoing research will continue to refine its use and expand the possibilities for long-term drug-free remission in type 2 diabetes.